CNTA
Centessa Pharmaceuticals plcHealthcare · $6.3B market cap
Verdict
We can't put a fair value on CNTA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow CNTA
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds CNTA right now. In Q2 2026, 1 sold out. Who we track
Moves in Q2 2026
Sold out: Lee Ainslie
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Jun 25, 2026. How the Payback Price works